The company's pipeline products include dronabinol for the treatment of obstructive sleep apnea, CX1739 for chronic central sleep apnea, and CX717 and CX1942 for respiratory depression or vaso-occlusive passes associated with sickle cell disease. RespireRx Pharmaceuticals Inc. is also developing a pipeline of new drug products based on their broad patent portfolios across two distinct drug platforms: Pharmaceutical Cannabinoids and Neuromodulators, including AMPAkines and GABAkines, for the treatment of CNS-driven neurobehavioral and cognitive disorders, such as ADHD and epilepsy, where their lead ampakine produced rapid, statistically significant improvement in adult patients with ADHD.